glp 1 egfr cut off GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity BJD

This blog will explore the role of GLP-1s in metabolic health, their potential when microdosed, their intersection with autoimmune diseases, and their impact on inflammation through a functional medicine lens

While we still envision a long runway for growth in these categories, the healthcare industry seeks to replicate success in other illnesses and expand the addressable market for these therapies even further

The vial sits on the counter

How much varies from person to person depending on starting weight, dosage, and how well you stick to diet and exercise changes

Although publication bias should always be considered (Jennings & Van Horn, 2012), neuroimaging studies are likely more susceptible to confirmation bias due to high analytical flexibility (Mller et al., 2018)